Affimed NV (NASDAQ:AFMD) shares shot up 5% during trading on Friday . The stock traded as high as $3.16 and last traded at $3.13, 1,238,869 shares were traded during trading. An increase of 47% from the average session volume of 843,858 shares. The stock had previously closed at $2.98.
Several research firms have commented on AFMD. Svb Leerink began coverage on shares of Fate Therapeutics in a report on Thursday, March 28th. They set an “outperform” rating and a $20.00 price objective for the company. ValuEngine raised shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, March 29th. Zacks Investment Research downgraded shares of EXACT Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. Leerink Swann initiated coverage on shares of Affimed in a report on Thursday, March 28th. They issued an “outperform” rating and a $4.17 price target for the company. Finally, Laidlaw set a $10.00 price target on shares of Affimed and gave the company a “buy” rating in a report on Wednesday, July 3rd. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $5.63.
The company has a current ratio of 3.17, a quick ratio of 3.16 and a debt-to-equity ratio of 0.03. The company’s fifty day moving average price is $3.01. The firm has a market capitalization of $184.99 million, a PE ratio of -8.24 and a beta of 2.84.
Affimed (NASDAQ:AFMD) last announced its quarterly earnings results on Wednesday, May 22nd. The biopharmaceutical company reported $0.03 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.19. Affimed had a negative net margin of 29.04% and a negative return on equity of 23.61%. The firm had revenue of $12.89 million during the quarter, compared to the consensus estimate of $6.77 million. As a group, research analysts expect that Affimed NV will post -0.28 EPS for the current fiscal year.
Large investors have recently made changes to their positions in the stock. D. E. Shaw & Co. Inc. bought a new position in shares of Affimed in the 4th quarter valued at about $36,000. Bourgeon Capital Management LLC purchased a new stake in Affimed in the 1st quarter worth about $42,000. Sigma Planning Corp purchased a new stake in Affimed in the 1st quarter worth about $46,000. Weiss Asset Management LP raised its position in Affimed by 69.7% in the 1st quarter. Weiss Asset Management LP now owns 29,877 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 12,271 shares during the period. Finally, Deutsche Bank AG raised its position in Affimed by 2,243.6% in the 4th quarter. Deutsche Bank AG now owns 49,074 shares of the biopharmaceutical company’s stock worth $152,000 after purchasing an additional 46,980 shares during the period. 37.50% of the stock is owned by hedge funds and other institutional investors.
About Affimed (NASDAQ:AFMD)
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Recommended Story: Earnings Per Share
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.